Front-line therapy of advanced ovarian cancer: new approaches

Area of Science:

• Oncology
• Clinical Research
• Pharmacology

Background:

• Ovarian cancer survival has improved, but primarily through later-line treatments, not first-line therapy.
• First-line treatment for ovarian cancer has seen minimal improvement in the last 15 years.
• Developing novel treatments to extend time to first progression and overall survival is a critical research objective.

Purpose of the Study:

• To review ongoing randomized trials of PARP inhibitors and immune checkpoint inhibitors in ovarian cancer.
• To discuss the potential benefits and challenges associated with these novel therapeutic agents.
• To provide an overview of emerging research directions in ovarian cancer treatment.

Main Methods:

• Review of ongoing randomized clinical trials.
• Focus on trials investigating PARP inhibitors.
• Focus on trials investigating immune checkpoint inhibitors (immunotherapy).

Main Results:

• Ongoing trials are evaluating PARP inhibitors and immune checkpoint inhibitors.
• The potential benefits of these agents in ovarian cancer are under investigation.
• Challenges associated with the use of these new agents are being considered.

Conclusions:

• Improvements in ovarian cancer outcomes from new trials may present interpretation challenges.
• Outcome data must be assessed within the context of clinical benefit and health-economic impact.
• The high cost of combination targeted therapy trials necessitates careful health-economic evaluation.